New York, USA, July 25, 2022 (GLOBE NEWSWIRE) -- Liver Cancer Pipeline Insight | Clinical Trial Research Evaluation Report
DelveInsight’s liver cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for liver cancer treatment.
DelveInsight’s 'Liver Cancer Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline liver cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the liver cancer pipeline domain.
Key Takeaways from the Liver Cancer Pipeline Report
- DelveInsight’s liver cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for liver cancer treatment.
- Key liver cancer companies such as Genentech, Virogin Biotech, Beijing Immunochina Medical Science & Technology Co., Ltd., Mina Alpha Limited, Amgen, Jiangsu HengRui Medicine Co., Ltd., Abbisko Therapeutics Co, Ltd, Medivir, Glaxo SmithKline, Teclison, Genoscience Pharma, Eureka Therapeutics Inc., Qurient Co., Ltd., Bristol-Myers Squibb, Lion TCR Pte. Ltd., Leap Therapeutics, TriSalus Life Sciences, Inc., Highlight Therapeutics, Hoffmann-La Roche, Provectus Biopharmaceuticals, Inc., Pfizer, Eisai Inc., GenVivo, Inc., Tvardi Therapeutics, Shanghai Miracogen Inc., Takeda, Bavarian Nordic, Intensity Therapeutics, Arbele Pty Ltd, Quadriga Biosciences, Inc., Klus Pharma, Nanobiotix, Takara Bio Inc., TaiRx, Inc., Can Fite Biopharma, Sirnaomics, Blueprint Medicines Corporation,Surface Oncology, Yiviva Inc., AVEO Pharmaceuticals, Inc., TCM Biotech International, Suzhou Suncadia Biopharmaceuticals Co., Ltd., T-ACE Medical Co., Ltd, Beijing Syngentech Co., Ltd., Sinocelltech Ltd., Abivax S.A., Suzhou Kintor Pharmaceutical Inc, Abbisko Therapeutics Co, Ltd, Polaris Group, Shanghai Henlius Biotech, Virogin Biotech Canada Ltd, Vaxcell Bio, Co., Ltd., Chugai Pharmaceutical, BeiGene, Taizhou Hanzhong biomedical co. LTD, CStone Pharmaceuticals, Antengene Corporation, Beijing Shenogen Biomedical Co., Ltd, PharmaEssentia, CARsgen Therapeutics Co., Ltd., Nanjing Legend Biotech Co., and others are evaluating novel liver cancer drugs candidate to improve the treatment landscape.
- Promising liver cancer pipeline therapies in various stages of development include Tiragolumab, VG161, IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561, ET140203, Q702, Relatlimab, LioCyx-M, DKN-01, SD-101, BO-112, RO7119929, PV-10, PF-07263689, E7386, GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705, BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20, HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.
- In June 2022, Teclison announced the peer-reviewed publication of a study demonstrating the safety, tolerability, and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer.Tirapazamine (TPZ) with conventional trans-arterial chemoembolization had a good safety profile and promising efficacy signals in early- and intermediate-stage liver cancer, including in patients who had progression or recurrence after standard therapy.
- In May 2022, SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC, and HCC. Confirmed partial responses (PR) were observed in two patients who received SRF388 monotherapy treatment: one in non-small-cell lung cancer (NSCLC) (previously reported) and one in clear cell renal cell carcinoma (RCC). In addition, a PR was observed in a patient who was treated with SRF388 in combination with pembrolizumab for hepatocellular carcinoma (HCC).
- In May 2022, Kintor Pharmaceutical Limited announced the first patient dosing in the United States of its multi-regional phase II clinical trial (NCT05178043) of ALK-1 antibody (GT90001) and Nivolumab (Opdivo) combination therapy for the treatment of advanced Hepatocellular Carcinoma (HCC).
- In April 2022, Tvardi Therapeutics, Inc. announced that its lead product, TTI-101, had been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).
- In January 2022, MiNA Therapeutics Limited announced that it has dosed the first patient in a global Phase 2 clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer).
- In January 2022, Abivax SA announced the detailed results of the dose escalation phase of its clinical phase 1/2 study conducted with ABX196 to treat hepatocellular carcinoma (HCC). In this study, heavily pre-treated hepatocellular cancer (HCC) patients were administered ABX196 in combination with checkpoint inhibitor nivolumab, including patients who were previously exposed to checkpoint inhibitor treatments. These results support the further clinical development of ABX196 in the HCC setting.
- In December 2021, Medivir AB announced that the first patient with hepatocellular carcinoma (HCC) had been dosed with MIV-818 in a phase 1b/2a combination study with the company's candidate drug MIV-818. In the study, MIV-818 will be given in combination with two other medicines, either with Lenvima®, a tyrosine kinase inhibitor or with Keytruda®, an anti-PD-1 checkpoint inhibitor. Lenvima® and Keytruda®, respectively, are currently approved as monotherapy treatments for HCC.
- In November 2021, Eureka Therapeutics, Inc., announced the initiation of ARYA-2, a Phase I/II open-label, dose-escalation clinical trial of ET140203 ARTEMIS® T-cell therapy in pediatric patients with relapsed or refractory hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), or hepatocellular carcinoma (HCC).
Request a sample and discover the recent advances in liver cancer treatment @ Liver Cancer Pipeline Outlook
The liver cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage liver cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the liver cancer pipeline landscape.
Liver Cancer Overview
Liver cancer is a type of cancer that begins in the liver. It is a dangerous tumor that commonly occurs in the context of chronic liver disease and cirrhosis. Primary liver cancer, also known as hepatocellular carcinoma (HCC), is the fifth most prevalent cancer in men, the seventh most common cancer in women, and the third-largest cause of cancer death globally. Hepatocellular carcinoma (HCC), the most common kind of liver cancer, is formed from hepatocytes and accounts for more than 80% of all occurrences of liver cancer. The 5-year liver cancer survival rate for persons who receive a liver transplant is in the 60-70% range.
Most persons have no symptoms in the early stages of primary liver cancer; most persons have no symptoms. When signs and liver cancer symptoms do occur, they may include loss of appetite, nausea and vomiting, abdominal swelling, white, chalky stools, and others. Liver cancer causes are sometimes known, such as chronic hepatitis infections. However, liver cancer can occur in persons with no underlying diseases, and it is unknown what causes it. Several tests and procedures such as blood tests, imaging tests, and biopsy are used for liver cancer diagnosis.
Find out more about liver cancer chemotherapy drugs @ Liver Cancer Drug Trials
A snapshot of the Liver Cancer Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| ADI-PEG20 | Polaris Group | Phase III | Arginine deiminase replacement | Intramuscular |
| SRF388 | Surface Oncology | Phase II | NA | Intravenous |
| MTL-CEBPA | MiNA Therapeutics | Phase II | RNA interference | Intravenous |
| VG161 | Virogin Biotech Ltd. | Phase II | Programmed cell death-1 ligand-1 inhibitor | Intratumoural |
| ET140203 | Eureka Therapeutics | Phase I/II | T lymphocyte replacement | Parenteral |
| Fostroxacitabine bralpamide | Medivir | Phase I/II | DNA synthesis inhibitor | Oral |
| ABSK 011 | Abbisko Therapeutics | Phase II | Type 4 fibroblast growth factor receptor antagonist | Oral |
| TAK-500 | Takeda | Phase I | MPYS protein stimulant | Intravenous |
| PTX-9908 | TCM Biotech International Corp. | Phase I/II | CXCR4 receptor modulator | Intravenous |
Learn more about the novel and emerging liver cancer pipeline therapies @ Liver Cancer Clinical Trials
Liver Cancer Therapeutics Assessment
The liver cancer pipeline report proffers an integral view of the liver cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Liver Cancer Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous
- Therapeutics Assessment By Molecule Type: Monoclonal antibodies, Peptides, Polymer, Small molecule, Immunotherapy
- Therapeutics Assessment By Mechanism of Action: RNA interference, Angiogenesis inhibitors, APEX1 protein inhibitors, DNA apurinic apyrimidinic site lyase inhibitors, DNA synthesis inhibitors, Arginine deiminase replacements, Type 1 fibroblast growth factor receptor antagonists, Vascular endothelial growth factor receptor-2 antagonists, Type 4 fibroblast growth factor receptor antagonists
- Key Liver Cancer Companies: Genentech, Virogin Biotech, Beijing Immunochina Medical Science & Technology Co., Ltd., Mina Alpha Limited, Amgen, Jiangsu HengRui Medicine Co., Ltd., Abbisko Therapeutics Co, Ltd, Medivir, GlaxoSmithKlinevh, Teclison, Genoscience Pharma, Eureka Therapeutics Inc., Qurient Co., Ltd., Bristol-Myers Squibb, Lion TCR Pte. Ltd., Leap Therapeutics, TriSalus Life Sciences, Inc., Highlight Therapeutics, Hoffmann-La Roche, Provectus Biopharmaceuticals, Inc., Pfizer, Eisai Inc., GenVivo, Inc., Tvardi Therapeutics, Shanghai Miracogen Inc., Takeda, Bavarian Nordic, Intensity Therapeutics, Arbele Pty Ltd, Quadriga Biosciences, Inc., Klus Pharma, Nanobiotix, Takara Bio Inc., TaiRx, Inc., Can Fite Biopharma, Sirnaomics, Blueprint Medicines Corporation,Surface Oncology, Yiviva Inc., AVEO Pharmaceuticals, Inc., TCM Biotech International, Suzhou Suncadia Biopharmaceuticals Co., Ltd., T-ACE Medical Co., Ltd, Beijing Syngentech Co., Ltd., Sinocelltech Ltd., Abivax S.A., Suzhou Kintor Pharmaceutical Inc, Abbisko Therapeutics Co, Ltd, Polaris Group, Shanghai Henlius Biotech, Virogin Biotech Canada Ltd, Vaxcell Bio, Co., Ltd., Chugai Pharmaceutical, BeiGene, Taizhou Hanzhong biomedical co. LTD, CStone Pharmaceuticals, Antengene Corporation, Beijing Shenogen Biomedical Co., Ltd, PharmaEssentia, CARsgen Therapeutics Co., Ltd., Nanjing Legend Biotech Co., and others
- Key Liver Cancer Pipeline Therapies: Tiragolumab, VG161, IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561, ET140203, Q702, Relatlimab, LioCyx-M, DKN-01, SD-101, BO-112, RO7119929, PV-10, PF-07263689, E7386, GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705, BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20, HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.
Dive deep into rich insights for chemo drugs for liver cancer treatment, visit @ T-cell Therapy for Liver Cancer Treatment
Table of Contents
| 1. | Liver Cancer Pipeline Report Introduction |
| 2. | Liver Cancer Pipeline Report Executive Summary |
| 3. | Liver Cancer Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Liver Cancer Pipeline Therapeutics |
| 6. | Liver Cancer Pipeline: Late Stage Products (Pre-registration) |
| 7. | Liver Cancer Pipeline: Late Stage Products (Phase III) |
| 7.1 | ADI-PEG20: Polaris Group |
| 8. | Liver Cancer Pipeline: Mid Stage Products (Phase II) |
| 8.1 | SRF388: Surface Oncology |
| 9. | Liver Cancer Pipeline: Early Stage Products (Phase I) |
| 9.1 | TAK-500: Takeda |
| 10. | Liver Cancer Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Liver Cancer Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Liver Cancer Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the liver cancer pipeline therapeutics, reach out @ Liver Cancer Therapy
Related Reports
Liver Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key liver cancer companies including Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, among others.
Liver Cancer Epidemiology Forecast
Liver Cancer Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted liver cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Advanced Liver Cancer Pipeline
Advanced Liver Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced liver cancer companies, including Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, among others.
Metastatic Liver Cancer Pipeline
Metastatic Liver Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic liver cancer companies, including Celldex Therapeutics, Takeda, Megapro Biomedical Company, among others.
Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced liver cancer companies including Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, among others.
Advanced Liver Cancer Epidemiology Forecast
Advanced Liver Cancer Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted advanced liver cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market
Related Healthcare Blogs
Small Cell Lung Cancer Treatment Outlook
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
